COVID-19
Pfizer announced that Dr. William Pao, M.D., Ph.D., will take on the role of executive vice president and chief development officer as of March 21.
Microbiologics, Inc. commemorated its 50th anniversary in 2021 by playing a key role in helping the world manage the COVID-19 pandemic.
Novavax is finally submitting an Emergency Use Authorization request to the U.S. Food and Drug Administration for its COVID-19 vaccine candidate, NVX-CoV2373, a protein-based vaccine.
WRNMC researchers have found a way to create a vaccine that can recognize multiple spike proteins at once by using ferritin. Here’s more about pan coronavirus vaccine.
News that a subvariant of the Omicron variant has appeared in the U.S. and parts of Europe doesn’t seem like good news. The latest data suggest it’s 1.5 times more transmissible than the original Omicron variant, but not necessarily deadlier.
Clinical trial news definitely picked up this final week of January. Here’s a look.
Researchers are expressing concern about a subvariant of Omicron dubbed BA.2 that appears to be tearing through Denmark. For that and more COVID-19 news, continue reading.
Although most of the news about the effectiveness and endurance of COVID-19 vaccines has focused on antibody titers, not as much has been reported on their effect on other parts of the immune system that offer longer-term protection, such as T cells. For that and more, continue reading.
Pfizer hopes to step in to ensure that no trade secrets are disclosed when the regulatory agency begins to share that information.
In the last two years, the sheer volume of scientific research focused on COVID-19 has been astounding—thousands of clinical studies, dozens of vaccines and new compounds, and hundreds of approved drugs tested for efficacy against COVID-19.
PRESS RELEASES